Based on these findings, trastuzumab-containing regimens emerge as a preferable and recommended choice in clinical practice for managing HER2-positive breast cancer.<h4>Systematic review registration</h4>PROSPERO, identifier CRD42023414348. Here, ERBB2 is linked to breast carcinoma.